CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

NCT06777979 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Mesna
DEVICE: CD19-CD22 CAR T cell infusion

Sponsor

St. Jude Children's Research Hospital